CATX
Perspective Therapeutics, Inc.
There isn't enough reported data to score CATX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CATX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
CATX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CATX PE Valuation
CATX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CATX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CATX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CATX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.25 | +$0.46 |
| Q2 2026 | -$1.33 | +$0.24 |
| Q1 2026 | -$1.40 | +$0.06 |
| Q4 2025 | -$1.40 | +$0.01 |
| Q3 2025 | -$1.71 | -$0.94 |
| Q2 2025 | -$1.57 | -$0.61 |
| Q1 2025 | -$1.46 | -$0.28 |
| Q4 2024 | -$1.41 | -$0.43 |
CATX is still losing money, but less than at its worst: $1.25 per share over the past year, against $1.71 at its worst in late 2025.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CATX on earnings quality, reporting a profit while its opponent remains loss making.
CATX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $2.2M | +27% |
| Q2 2023 | $2.1M | -17% |
| Q1 2023 | $2.1M | -29% |
| Q4 2022 | $1.8M | -35% |
| Q3 2022 | $1.7M | -33% |
| Q2 2022 | $2.5M | -7.6% |
| Q1 2022 | $2.9M | +12% |
| Q4 2021 | $2.8M | +19% |
UNH has the stronger quarterly revenue trend. Revenue is down 386% for CATX versus down 0.4% for UNH.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2023 | -482% | -237 points |
| Q2 2023 | -545% | -461 points |
| Q1 2023 | -544% | -497 points |
| Q4 2022 | -175% | -117 points |
| Q3 2022 | -245% | -156 points |
| Q2 2022 | -84% | -44 points |
| Q1 2022 | -47% | -18 points |
| Q4 2021 | -58% | -21 points |
CATX's operating margin was −482% last quarter, down 237 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
CATX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$35.9M | -$17.6M |
| Q2 2026 | -$34.8M | -$13.9M |
| Q1 2026 | -$38.3M | -$12.1M |
| Q4 2025 | -$29.7M | +$11.5M |
| Q3 2025 | -$18.3M | +$8.1M |
| Q2 2025 | -$21M | -$11.1M |
| Q1 2025 | -$26.2M | -649% |
| Q4 2024 | -$41.2M | -$32.1M |
CATX has burned cash in almost every quarter: −$139M over the past year, against −$107M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CATX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CATX Net Leverage
CATX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CATX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 2.7 | Oversold |
CATX's weekly RSI is 24 (oversold) and its Stochastic is 3 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CATX PE vs Healthcare Sector
CATX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CATX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.82 | 54% below |
| 20 week MA | $2.57 | 67% below |
| 50 week MA | $3.29 | 74% below |
| 100 week MA | $3.19 | 74% below |
| 200 week MA | $5.58 | 85% below |
CATX is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CATX on trend strength, trading above more of its moving averages.
CATX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.12 | $4.70 | -23% |
| 2021 | $4.70 | $4.06 | -14% |
| 2022 | $4.06 | $2.90 | -29% |
| 2023 | $2.90 | $4.02 | +39% |
| 2024 | $4.02 | $3.19 | -21% |
| 2025 | $3.19 | $2.88 | -9.7% |
| 2026 YTD | $2.88 | $0.84 | -71% |
CATX has finished lower in five of the last six years. It's down 71% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CATX on returns for 2026, with the stronger performance.